Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Buy
58
NMRA Quote, Financials, Valuation and Earnings
Last price:
$2.22
Seasonality move
:
-54.68%
Day range:
$2.21 - $2.57
52-week range:
$0.61 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.81x
Volume:
2.2M
Avg. volume:
1.7M
1-year change:
-6.33%
Market cap:
$370.9M
Revenue:
--
EPS (TTM):
-$1.46
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NMRA
Neumora Therapeutics, Inc.
|
-- | -$0.33 | -- | -9.04% | $9.33 |
|
NAUT
Nautilus Biotechnology, Inc.
|
-- | -$0.15 | -- | -- | $2.50 |
|
PBYI
Puma Biotechnology, Inc.
|
$68.6M | $0.23 | 16.12% | -41.13% | $3.50 |
|
PROK
ProKidney Corp.
|
-$39.4K | -$0.15 | -100% | -9.1% | $6.50 |
|
VTYX
Ventyx Biosciences, Inc.
|
-- | -$0.36 | -- | -12.11% | $13.38 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NMRA
Neumora Therapeutics, Inc.
|
$2.22 | $9.33 | $370.9M | -- | $0.00 | 0% | -- |
|
NAUT
Nautilus Biotechnology, Inc.
|
$2.06 | $2.50 | $260.2M | -- | $0.00 | 0% | -- |
|
PBYI
Puma Biotechnology, Inc.
|
$6.11 | $3.50 | $307.9M | 8.25x | $0.00 | 0% | 1.44x |
|
PROK
ProKidney Corp.
|
$2.34 | $6.50 | $331.2M | -- | $0.00 | 0% | 411.04x |
|
VTYX
Ventyx Biosciences, Inc.
|
$13.81 | $13.38 | $985.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NMRA
Neumora Therapeutics, Inc.
|
13.19% | 4.241 | 6.81% | 6.64x |
|
NAUT
Nautilus Biotechnology, Inc.
|
13.77% | 3.788 | 25.3% | 14.63x |
|
PBYI
Puma Biotechnology, Inc.
|
26.26% | 0.733 | 15.34% | 1.57x |
|
PROK
ProKidney Corp.
|
-0.42% | 4.194 | 0.26% | 9.35x |
|
VTYX
Ventyx Biosciences, Inc.
|
4.98% | 6.062 | 4.52% | 17.11x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NMRA
Neumora Therapeutics, Inc.
|
-$23K | -$52.7M | -98.72% | -102.63% | -- | -$46.6M |
|
NAUT
Nautilus Biotechnology, Inc.
|
-$1.6M | -$15.5M | -27.96% | -32.15% | -- | -$11.5M |
|
PBYI
Puma Biotechnology, Inc.
|
$42.3M | $9.6M | 23.32% | 38.49% | 17.57% | $9.7M |
|
PROK
ProKidney Corp.
|
-$1.2M | -$38.5M | -42.03% | -42.51% | -17759.91% | -$31.8M |
|
VTYX
Ventyx Biosciences, Inc.
|
-$326K | -$24.9M | -43.77% | -45.75% | -- | -$17.6M |
Neumora Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns NMRA or NAUT?
Nautilus Biotechnology, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of --. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Nautilus Biotechnology, Inc.'s return on equity of -32.15%.
Company Gross Margin Earnings Per Share Invested Capital NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M NAUTNautilus Biotechnology, Inc.-- -$0.11 $196.1M -
What do Analysts Say About NMRA or NAUT?
Neumora Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 320.42%. On the other hand Nautilus Biotechnology, Inc. has an analysts' consensus of $2.50 which suggests that it could grow by 21.36%. Given that Neumora Therapeutics, Inc. has higher upside potential than Nautilus Biotechnology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Nautilus Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRANeumora Therapeutics, Inc.3 2 0 NAUTNautilus Biotechnology, Inc.2 0 0 -
Is NMRA or NAUT More Risky?
Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nautilus Biotechnology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NMRA or NAUT?
Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nautilus Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Nautilus Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRA or NAUT?
Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Nautilus Biotechnology, Inc. quarterly revenues of --. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Nautilus Biotechnology, Inc.'s net income of -$13.6M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Nautilus Biotechnology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus -- for Nautilus Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M NAUTNautilus Biotechnology, Inc.-- -- -- -$13.6M
-
Which has Higher Returns NMRA or PBYI?
Puma Biotechnology, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of 16.24%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.
Company Gross Margin Earnings Per Share Invested Capital NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M PBYIPuma Biotechnology, Inc.77.65% $0.17 $156.3M -
What do Analysts Say About NMRA or PBYI?
Neumora Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 320.42%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -42.72%. Given that Neumora Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRANeumora Therapeutics, Inc.3 2 0 PBYIPuma Biotechnology, Inc.0 1 0 -
Is NMRA or PBYI More Risky?
Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.
-
Which is a Better Dividend Stock NMRA or PBYI?
Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRA or PBYI?
Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 1.44x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M PBYIPuma Biotechnology, Inc.1.44x 8.25x $54.5M $8.8M
-
Which has Higher Returns NMRA or PROK?
ProKidney Corp. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of -16517.51%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat ProKidney Corp.'s return on equity of -42.51%.
Company Gross Margin Earnings Per Share Invested Capital NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M PROKProKidney Corp.-544.24% -$0.12 $322.6M -
What do Analysts Say About NMRA or PROK?
Neumora Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 320.42%. On the other hand ProKidney Corp. has an analysts' consensus of $6.50 which suggests that it could grow by 177.78%. Given that Neumora Therapeutics, Inc. has higher upside potential than ProKidney Corp., analysts believe Neumora Therapeutics, Inc. is more attractive than ProKidney Corp..
Company Buy Ratings Hold Ratings Sell Ratings NMRANeumora Therapeutics, Inc.3 2 0 PROKProKidney Corp.4 3 0 -
Is NMRA or PROK More Risky?
Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ProKidney Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NMRA or PROK?
Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProKidney Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. ProKidney Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRA or PROK?
Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than ProKidney Corp. quarterly revenues of $217K. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than ProKidney Corp.'s net income of -$35.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while ProKidney Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 411.04x for ProKidney Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M PROKProKidney Corp.411.04x -- $217K -$35.8M
-
Which has Higher Returns NMRA or VTYX?
Ventyx Biosciences, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of --. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Ventyx Biosciences, Inc.'s return on equity of -45.75%.
Company Gross Margin Earnings Per Share Invested Capital NMRANeumora Therapeutics, Inc.-- -$0.35 $152.2M VTYXVentyx Biosciences, Inc.-- -$0.32 $201.4M -
What do Analysts Say About NMRA or VTYX?
Neumora Therapeutics, Inc. has a consensus price target of $9.33, signalling upside risk potential of 320.42%. On the other hand Ventyx Biosciences, Inc. has an analysts' consensus of $13.38 which suggests that it could fall by -3.15%. Given that Neumora Therapeutics, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Ventyx Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings NMRANeumora Therapeutics, Inc.3 2 0 VTYXVentyx Biosciences, Inc.0 8 0 -
Is NMRA or VTYX More Risky?
Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ventyx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock NMRA or VTYX?
Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ventyx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Ventyx Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NMRA or VTYX?
Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Ventyx Biosciences, Inc. quarterly revenues of --. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Ventyx Biosciences, Inc.'s net income of -$22.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Ventyx Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus -- for Ventyx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NMRANeumora Therapeutics, Inc.-- -- -- -$56.8M VTYXVentyx Biosciences, Inc.-- -- -- -$22.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
